VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today reported financial results for the first quarter ending March 31, 2020 and provided a corporate update.

What happened Shares of VBI Vaccines (NASDAQ: VBIV) jumped 11.3% on Wednesday after the company reported its first-quarter financial results and updated investors on its clinical-stage drug pipeline. So what VBI Vaccines' update detailed its plans to file for Food and Drug Administration approval of its hepatitis B vaccine, Sci-B-Vac, in Q4.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the pricing of its previously announced underwritten public offering of 45,454,545 common shares, at a public offering price of US$1.10 per share. VBI also granted the underwriters a 30-day option to purchase up to an additional 6,818,181 common shares at the public offering price less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately US$50 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about April 24, 2020, subject to satisfaction of customary closing conditions.

The question keeping the world up at night: when will a COVID-19 vaccine be ready? Since China released the virus’ genetic sequence on January 10, researchers in several countries have been working around the clock to develop an effective and safe vaccine. Even though the rapid pace of the development process has been impressive to say the least, patience is required as the task at hand certainly won’t be an easy one.However, in recent days, a few healthcare companies have made strides in the advancement of a COVID-19 vaccine, inspiring hope that we are well on our way to stamping out this deadly virus. Seasoned Wall Street observers know that the race’s winner is bound for glory, with the market standing to reward its efforts handsomely.Bearing this in mind, we used TipRanks’ database to take a closer look at three healthcare stocks emerging as strong contenders in the world’s most talked about race. Based on the data, each of these Buy-rated names could see significant upside should the outcome be in their favor.Inovio Pharmaceuticals (INO)Yet again, Wall Street focus has locked in on Inovio Pharmaceuticals. The company, which has developed DNA technology called SynCon and its CELLECTRA electroporation delivery system to stimulate immune responses to target virus-infected or tumor cells, has made significant headway in its COVID-19 vaccine development program. As a result, one analyst believes additional gains are in store on top of its already achieved 145% year-to-date rise.Writing for Cantor, five-star analyst Charles Duncan notes that on April 6, not only was the first healthy volunteer dosed with INO’s experimental vaccine, INO-4800, but the FDA also accepted the candidate’s Investigational New Drug (IND) application. During the study, the company will dose 40 healthy volunteers, with preliminary safety and immunogenicity data expected by late summer.“We note the speed with which this program has moved from ‘idea to action,’ as Inovio was able to go from obtaining the genetic sequence on 1/10 to designing INO-4800, conducting preclinical studies to support an IND, and manufacturing clinical grade product to initiate the study in less than three months. As we previously opined, we believe that Inovio’s platform is well-suited for a rapid turnaround of a vaccine candidate, as the company has substantial experience developing vaccines targeting numerous viruses, including MERS-CoV, Ebola, Zika, and Lassa fever, and DNA-based vaccines are faster to develop and manufacture than protein/viral biologics,” Duncan commented.Looking specifically at INO’s MERS vaccine candidate, INO-4700, it was able to generate statistically significant T cell responses in 71% of participants after two vaccinations and in 76% of participants after three vaccinations, implying that cellular immunity was produced. In Duncan’s opinion, this demonstrates that the company’s platform can stimulate an immune response, as well as “...the potential for INO-4800 to rapidly make a positive impact on the COVID-19 pandemic, or even potentially future outbreaks, with an effective vaccine.”It should come as no surprise, then, that Duncan left both an Overweight rating and $12 price target on the stock. Should this target be met, a twelve-month gain of 48% could be in the cards. (To watch Duncan’s track record, click here)Turning now to the rest of the Street, INO’s Moderate Buy consensus rating breaks down into 3 Buys and 2 Holds given in the last three months. At $10.25, the average price target is less aggressive than Duncan’s and suggests 26% upside potential. (See Inovio stock analysis on TipRanks)VBI Vaccines (VBIV)VBI Vaccines has already developed a hepatitis B vaccine, Sci-B-Vac, which is on the market in Israel and has completed a Phase 3 development program in the U.S., Europe and Canada. Now, VBIV is taking on COVID-19, and some members of the Street like its chances.After the company revealed it had partnered with the National Research Council of Canada (NRC) to advance a pan-coronavirus vaccine targeting not only COVID-19, but also MERS and SARS, Canaccord Genuity’s John Newman sees VBIV’s long-term growth narrative as being even stronger.Newman notes that preclinical development is moving right on track, and a clinical trial could even start by year end 2020. As per the terms of the agreement, VBIV will utilize the NRC’s clinical expertise and COVID-19 spike antigens as well as its own enveloped Virus-Like Particle (eVLP) platform, coronavirus antigens and viral vaccine expertise to identify a lead candidate to focus on.Part of the five-star analyst’s enthusiasm is related to the technology itself, with its eVLP platform enabling the production of antigens with proper trimeric conformation, which has been a key component in the design of other viral vaccines. On top of this, the 3D conformation of viral antigens could be important in the development of an effective vaccine.Expounding on VBIV’s strategy, Newman stated, “We believe VBI's approach toward a pan-coronavirus vaccine candidate is rationally designed to stimulate the production of broadly reactive coronavirus antibodies, which could protect against future coronavirus strains. This strategy is important since SARSCoV-2 is an RNA virus prone to mutation with some evidence of antigenic shift being described in the literature.”As Newman also still believes that Sci-B-Vac will be approved in the U.S. and Europe and sees the data readouts for VBI-1501 and VBI-1901 as potential catalysts, he stayed with the bulls. To this end, he reiterated a Buy rating and $4 price target, implying 317% upside potential. (To watch Newman’s track record, click here)Looking at the consensus breakdown, it has been relatively quiet when it comes to other analyst activity. Only one other analyst has thrown an opinion into the mix, but it was also bullish, making the consensus rating a Moderate Buy. Based on the $4.50 average price target, the potential twelve-month gain lands at 369%. (See VBI Vaccines stock analysis on TipRanks)Altimmune Inc. (ALT)As for the last name on our list, Altimmune’s approach focuses on mucosal immunity, with its COVID-19 vaccine candidate designed using its innovative intranasal platform technology. Following an Expert Call with the company’s management, Roth Capital analyst Yasmeen Rahimi believes it has a fighting chance in this race.Unlike its peers, ALT’s vaccine technology uses a replication-deficient adenovirus vector, serotype 5, to stimulate a broad immune response. One of the advantages of this design is that it enables vaccines to be delivered intranasally. This sends the vaccine vector directly to the respiratory tract’s mucosal membrane, where it produces mucosal immunity as the first line of defense against COVID-19. As a result, the Ad-COVID vector spurs antigen production inside the cell, which causes an immune response including cellular, humoral and antibody-mediated immunity.Rahimi added, “Specifically, these immune responses include production of high levels of neutralizing antibodies in the serum, in addition to effective T cell activation to help them recognize and kill cells that are infected with the virus. In comparison, traditional vaccines are injectables and do not usually induce mucosal immunity, making intranasal delivery a favorable attribute for ALT's vaccines.”Adding to the good news, only one dose of a vaccine using this platform is needed to produce a robust response. “Importantly, this can eliminate the need for repeat administrations, and can provide lasting protection which in our view is a key advantage especially in a widespread pandemic where there is a need to immunize as much of the population as possible in a short time frame,” Rahimi explained.Taking all of this into consideration, Rahimi tells investors that her bullish thesis remains very much intact. In line with this take, the four-star analyst maintained a Buy recommendation and $13 price target. This brings the upside potential to a whopping 310%. (To watch Rahimi’s track record, click here)Over the last three months, Rahimi was the only analyst that published a review on this stock, making the consensus rating a Moderate Buy. (See Altimmune price targets and analyst ratings on TipRanks)To find good ideas for stocks healthcare trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the formation of a Commercial Advisory Board consisting of leading experts in public health policy, epidemiology, and vaccine development. The Commercial Advisory Board will work closely with VBI’s management team on pre-commercialization and commercialization activities and strategy for the company’s pipeline programs.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that expanded immunologic and tumor response data from the ongoing Phase 1/2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (GBM) patients will be presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, to be held June 22-24, 2020.

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 28.57% and -49.70%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Companies In The News Are: KNSA, EYEG, VBIV, EYES

VBI Vaccines Inc. (NASDAQ: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced a collaboration with the National Research Council of Canada (NRC), Canada’s largest federal research and development organization, to develop a pan-coronavirus vaccine candidate, targeting COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS).

Is it May 2020 or March 2009? As Wall Street observers traverse the confused economic environment, flashbacks of the Great Recession are coming to mind. Those looking at the glass half empty will point out the bear market that emerged took 18 months to reach the lowest point. However, the optimists are singing a different tune.Among the bulls is Morgan Stanley’s head of U.S. equity strategy, Michael Wilson. In a recent note to clients, he argues that the current state of the market bears a striking resemblance to March 2009, the period in which the U.S. economy began to recover, with the S&P 500 embarking on what would become the longest bull-market run on record.“Markets are tracking the Great Financial Crisis period very closely in many ways,” Wilson wrote. To support this claim, the strategist highlights the fact that stocks are bouncing back in a “similar pattern," at the same time the amount of stocks, especially cyclicals, that have exceeded their 200-day moving average is on the rise. This is important as cyclicals usually lead the charge when a market recovery kicks off. Wilson also notes that the equity-risk premium, or the expected earnings yield for the S&P 500 minus the ten-year Treasury yield, looks the same as it did in March 2009, which played into his decision to call a stock-market bottom on March 16 of this year.Taking Wilson’s views into consideration, risk-tolerant investors are on the hunt for promising names now trading at lower levels, specifically within the biotech space. As it just takes one positive catalyst like strong data or a favorable FDA ruling to send shares skyrocketing, massive returns are on the table. That being said, as the opposite also holds true, these stocks come with their fair share of risk.Acknowledging the risk involved, we used TipRanks’ database to pinpoint compelling, yet affordable biotech stocks. We found three trading for under $5 that have not only received enough bullish recommendations from analysts to earn a “Strong Buy” consensus rating, but also sport colossal upside potential.Gamida Cell Ltd. (GMDA)It has certainly been a rough week for Gamida Cell, which develops therapies that could potentially cure blood cancers and other blood diseases.On Tuesday, the company unveiled the pricing for its underwritten public offering of 13,333,334 ordinary shares, which landed at $4.50 per share. The fund raise sent shares tumbling, with GMDA walking away from the day’s trading session down 26%. However, the new share price, $4.42, offers an attractive entry point, according to the analyst community.Weighing in for Oppenheimer, five-star analyst Mark Breidenbach cites recently released positive top-line data from its randomized Phase 3 trial of omidubicel in patients receiving bone marrow transplants as a key component of his bullish thesis. The trial had 125 participants between the ages of 12-65 with high-risk hematologic malignances (AML, CML, MDS, lymphoma), and GMDA’s candidate was studied against standard umbilical cord blood (UCB) grafts.Not only did omidubicel meet its primary endpoint, but the asset’s failure rate came in at 4% while the UCBs had a failure rate of 12%. After the readout, the company announced that it plans on initiating a rolling BLA submission in the fourth quarter.Expounding on the implications of the results, Breidenbach stated, “While expecting to see full results are at a medical meeting later this year (likely ASH), we believe these data could support a 2021 FDA approval and help spur uptake at transplant centers.” He added, “We believe omidubicel has been de-risked with the successful Phase 3 results.”Adding to the good news, Breidenbach argues that the results show omidubicel is “competitive with more widely used grafts, including matched unrelated donor (MUD) and mismatched-related donor grafts.” He noted, “As such, these data may support wider adoption of omidubicel among transplant physicans, although longer follow-up will be required to assess relapse rates and treatment-related mortality.”Based on all of the above, Breidenbach keep an Outperform (i.e. Buy) rating on the stock. Along with his bullish call, he also bumped up the price target from $18 to $20. This implies upside potential of a massive 352%. (To watch Breidenbach’s track record, click here) Turning now to the rest of the Street, other analysts are on the same page. Only Buy ratings have been received in the last three months, 3, in fact, so the consensus rating is a Strong Buy. In addition, the $18 average price target puts the upside potential at 307%. (See Gamida Cell stock analysis on TipRanks)VBI Vaccines (VBIV)Using its enveloped virus-like particle (eVLP) platform, VBI Vaccines develops vaccines that could be capable of addressing unmet needs in infectious disease and immuno-oncology. With one analyst, Canaccord Genuity’s John Newman, expecting a “catalyst-rich” second half of the year for the company, its $2.49 share price could mean that now is the time to pull the trigger.The five-star analyst tells investors the fourth quarter of 2020 will see VBIV submit regulatory approval filings for Sci-B-Vac, its vaccine against hepatitis B. These will be comprised of data from the CONSTANT and PROTECT Phase 3 trials in the U.S., Europe and Canada. “We continue to expect the agencies will view Sci-B-Vac's regulatory applications favorably and expect approvals in 2021...We continue to believe a key factor for VBIV will be whether the Advisory Committee on Immunization Practices (ACIP) recommends Sci-B-Vac at a two-dose immunization schedule, for their commercial launch,” he commented.As for its chronic hepatitis B virus (HBV) therapy, VBI-2601, initial human proof-of-concept data from the Phase 1b/2a study could be published in the second half of this year as well.Looking at its VBI-1901 asset, which was designed for use in recurrent Glioblastoma Multiforme (rGBM) patients, expanded immunologic, tumor and clinical data from the GM-CSF arm and initial immunologic and tumor response data from the AS01B arm are slated for release mid-year and in Q4, respectively. “We look for continued positive data for VBI-1901 in GBM,” Newman said.If that wasn’t enough, a pan-coronavirus vaccine is in the works, with VBIV expecting IND-enabling animal testing for the candidate, VBI-2901, to start in the second quarter. On top of this, the company could have clinical candidates selected and enough clinical supply ready in Q4 2020.As VBIV’s operations through 2021 will most likely be supported by the $57.5 million equity raise last month and its $35.8 million in cash as of Q1 2020, it’s no wonder Newman is optimistic. In addition to maintaining a Buy recommendation, he did trim the price target by $1 to account for share dilution. That being said, the $3 figure still leaves room for a possible twelve-month gain of 20%. (To watch Newman’s track record, click here)Do other analysts agree with Newman? As it turns out, they do. With 100% Street support, or 3 Buy ratings to be exact, the consensus is unanimous: VBIV is a Strong Buy. At $4.33, the average price target is more aggressive and suggests 74% upside potential. (See VBI Vaccines stock analysis on TipRanks)Cyclacel Pharmaceuticals (CYCC)The last biotech on our list, Cyclacel Pharmaceuticals, uses cell cycle, transcriptional regulation and DNA damage response biology to develop cancer therapies. Currently going for $4.59 apiece, some members of the Street are telling investors to get onboard before shares take off on an upward trajectory.Writing for Roth Capital, analyst Jonathan Aschoff believes the strength of CYCC’s development program makes it a stand-out. The company is focused on solid tumors, with it conducting its clinical trials so that it can still report updated fadraciclib Phase 1 data with the higher frequency IV dosing schedule in advanced solid tumors, initial Phase 1 safety and PK results with oral fadraciclib as well as kick off its Phase 1/2 precision medicine trial in early 2021. It should be noted that oral fadraciclib has already demonstrated concordance with IV pharmacokinetics based on early clinical data.With this strong technology, Aschoff argues that CYCC is targeting the unmet need in the cyclin E overexpressing tumors of the breast, endometrium/uterus and ovaries space. “The solid tumor program is key to our CYCC valuation, as projected revenue from this cyclin E overexpressing population represents more than 70% of projected revenue. We note that cyclin E is overexpressed in one-third of HR+ breast cancer patients resistant to first-line therapy, where patients could receive fadraciclib alone or potentially in combination with hormonal therapy. This population, combined with resistant second-line ovarian and endometrial/uterine cancer patients with high cyclin E amount to just over 100,000 patients in the U.S.,” he explained.Additionally, CYCC is set to publish initial Phase 1 fadraciclib/ venetoclax results in rel/ref AML/MDS and CLL, initial Phase 1 sapacitabine/venetoclax results in rel/ref AML/MDS and initial Phase 1 CYC140 data in advanced leukemias. While Phase 1b/2 sapacitabine/olaparib results in BRCA mutant metastatic breast cancer are also expected, the timing is uncertain.Some investors have expressed concern regarding COVID-19's impact on the company’s trials, but Aschoff points out that thus far, CYCC hasn’t experienced any enrollment delays. He added, “CYCC recently announced its intent to study the potential of fadraciclib to be an early inhibitor of the detrimental inflammatory response observed in COVID-19 patients, specifically to induce MCL1 downregulation and apoptosis of inflammatory neutrophils.”Consider all of this combined with its $27.3 million cash position that will support its development programs through 2022, and it makes sense why Aschoff remains squarely in the bull camp. To this end, he reiterated a Buy rating and $24 price target, indicating 423% upside potential. (To watch Aschoff’s track record, click here)Like Aschoff, other analysts also take a bullish approach. CYCC’s Strong Buy consensus rating breaks down into 3 Buys and zero Holds or Sells. Given the $16.33 average price target, shares could soar 256% in the next year. (See Cyclacel stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters’ option to purchase additional shares. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by VBI, are approximately US$57.5 million. 52,272,726 common shares, at a public offering price of US$1.10 per share, were issued and sold in this offering, which includes 6,818,181 shares issued upon the exercise of the underwriters’ option to purchase additional shares.

Investors need to pay close attention to VBI Vaccines (VBIV) stock based on the movements in the options market lately.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has commenced an underwritten public offering of its common shares. VBI also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of common shares offered in the public offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Arvinas Inc (NASDAQ: ARVN) * Exelixis, Inc. (NASDAQ: EXEL) * GenMark Diagnostics, Inc (NASDAQ: GNMK) * Keros Therapeutics Inc (NASDAQ: KROS) * Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) * Moderna Inc (NASDAQ: MRNA) * OraSure Technologies, Inc. (NASDAQ: OSUR) * Repro-Med Systems, Inc. (NASDAQ: KRMD) * Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 21) * Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC)(announced pricing of $20 million common stock offering) * Nabriva Therapeutics PLC - ADR (NASDAQ: NBRV) * Viveve Medical Inc (NASDAQ: VIVE)Stocks In Focus Novartis' Cell Therapy Gets Regenerative Medicine Advanced Therapy Designation For Follicular Lymphoma Novartis AG (NYSE: NVS) said the FDA granted Regenerative Medicine Advanced Therapy designation to Kymriah for an investigational new indication to treat patients with relapsed or refractory follicular lymphoma. Kymriah is a CAR-T cell therapy and has already been approved for pediatric and young adult acute lymphoblastic leukemia, and adult diffuse large B-cell lymphoma.Actinium Prices Common Stock Offering at Discount Actinium Pharmaceuticals Inc (NYSE: ATNM) said it has priced its previously-announced underwritten public offering of 183.33 million shares at 15 cents per share. The company expects to raise gross proceeds of $27.5 million from the offering.The company said it intends to use the net proceeds to complete its ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate, Iomab-B, and support its BLA filing, among other things.The stock was slumping 27.94% to 17 cents in pre-market trading Wednesday.Immunic's Antiviral Investigational Assets Found Effective Against Coronavirus In Animal Studies Immunic Inc (NASDAQ: IMUX) reported that IMU-838, its lead asset has successfully demonstrated preclinical activity against SARS-CoV-2. More specifically, IMU-838 was observed to inhibit replication of clinical isolates of SARS-CoV-2 associated with COVID-19, the company said.The company said these positive results have encouraged it to prepare a clinical development program for IMU-838 as a potential treatment option for patients with COVID-19 and potential other, future viral pandemics.In premarket trading Wednesday, the stock was jumping 88.08% to $16.10. BioNTech, Pfizer Get German Regulatory Nod For Human Testing Of COVID-19 Vaccine Candidate BioNTech SE - ADR (NASDAQ: BNTX) and Pfizer Inc. (NYSE: PFE) said the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 1/2 clinical trial for BioNTech's BNT162 vaccine program to prevent COVID-19 infection. The companies are awaiting FDA nod to begin human testing in the U.S.View more earnings on GILDIn pre-market trading, BioNTech shares were soaring 52.15% to $64.30 and Pfizer was seen adding 5.56% to $37.60.Quest Begins Offering Antibody Testing For Coronavirus Quest Diagnostics Inc (NYSE: DGX) said it has begun to perform antibody testing for coronavirus using blood samples. The company already gives healthcare providers access to its molecular diagnostic laboratory testing.Gilead Strikes Immuno-oncology And Cell Therapy Collaboration With oNKo-innate Gilead Sciences, Inc. (NASDAQ: GILD), its Kite unit and oNKo-innate announced a 3-year cancer immunotherapy research collaboration to support the discovery and development of next-gen drug and engineered cell therapies focus on natural killer, or NK, cells.oNKo-innate will run screens to identify and validate targets to seed internal Gilead immuno-oncology discovery programs, while for Kite, oNKo will create and evaluate NK constructs for Kite's development of next-generation cell therapies.The stock was gaining 2.15% to $80.22 in pre-market trading.VBI Vaccines Announces Secondary Offering Of Common Stock VBI Vaccines Inc (NASDAQ: VBIV) announced that it has commenced an underwritten public offering of its common shares. The company said it intends to use the net proceeds to support the regulatory filings, pre- commercialization, and launch planning activities for Sci-B-Vac in the U.S., Europe, and Canada, for the continued advancement of its pipeline programs, and for general corporate purposes.In pre-market trading, the stock was slumping 30.13% to $1.09.met its co-primary efficacy endpoints and six key secondary endpoints. In addition, relugolix combination therapy was generally well-tolerated including minimal bone mineral density loss over 24 weeks.Myovant Reports Positive Results For Latestage Study of Drug to Treat Endometriosis-Related Pain Myovant Sciences Ltd (NYSE: MYOV) announced results from the Phase 3 SPIRIT 2 study of once-daily relugolix combination therapy in women with pain associated with endometriosis, which showed the study met its co-primary efficacy endpoints and six key secondary endpoints.In pre-market trading, shares were adding 7.08% to $12.40.On The Radar Earnings * Biogen Inc (NASDAQ: BIIB) (before the market opens) * Quest Diagnostics (before the market opens)See more from Benzinga * The Daily Biotech Pulse: Moderna Secures 3M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement * Gilead Analysts Break Down Remdesivir Data Readout From Compassionate Use(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has entered into a debt financing facility for up to $50 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.

Investors need to pay close attention to VBI Vaccines (VBIV) stock based on the movements in the options market lately.

As of late, it has definitely been a great time to be an investor in VBI Vaccines.

If you're interested in VBI Vaccines Inc. (NASDAQ:VBIV), then you might want to consider its beta (a measure of share...